JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

TransMedics Group Inc

Suletud

SektorTervishoid

130.6 2.1

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

128.42

Max

134.02

Põhinäitajad

By Trading Economics

Sissetulek

9.2M

35M

Müük

14M

157M

P/E

Sektori keskmine

59.064

37.461

Kasumimarginaal

22.181

Töötajad

728

EBITDA

10M

46M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+12.09% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. okt 2025

Turustatistika

By TradingEconomics

Turukapital

527M

4.1B

Eelmine avamishind

128.5

Eelmine sulgemishind

130.6

Uudiste sentiment

By Acuity

39%

61%

133 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

TransMedics Group Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2025, 19:15 UTC

Suurimad hinnamuutused turgudel

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Võrdlus sarnastega

Hinnamuutus

TransMedics Group Inc Prognoos

Hinnasiht

By TipRanks

12.09% tõus

12 kuu keskmine prognoos

Keskmine 144.5 USD  12.09%

Kõrge 170 USD

Madal 115 USD

Põhineb 11 Wall Streeti analüütiku instrumendi TransMedics Group Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

11 ratings

9

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

92.43 / 94.18Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

133 / 371 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat